Mattias Neyt, MSc, PhD

Mattias Neyt is an economist (Ghent University) and obtained a Ph.D. in 2006 from Ghent University with a dissertation entitled ‘Economic evaluation of medical innovations’. Since 2005, he has been working at the Belgian Health Care Knowledge Centre (KCE), an independent federal agency providing advice to policy makers, where he is senior health economist.

He has co-authored about 40 'Health Technology Assessment' (HTA) and ‘Health Services Research’ (HSR) projects about drugs, medical devices, diagnostics, screening, etc. He is author of about 70 peer-reviewed journal articles. He is author of the Belgian guidelines for economic evaluations, the European guidelines for measuring health-related quality of life, and the European guidance document on practical considerations for critically assessing economic evaluations. Member of the European ‘methodological and procedural guidance’ groep. Funder of ME-TA (Medical Evaluation and Technology Assessment) that conducts systematic reviews and HTAs for foreign non-profit organizations and provides professional training in HTA and economic evaluations.

Selection of publications (also related to professional activities other than ME-TA)

Neyt M, Luyten J, Desimpel F, Camberlin C, Primus-de Jong C, Verleye L. An economic evaluation of lung cancer screening with low-dose computed tomography in a high-risk population of (ex-)smokers in Belgium. Lung Cancer. 2025 Sep:207:108697. 

Neyt M, De Meester C, Devriese S, Marynen E, Beeckman D. Silicone adhesive multilayer foam dressings to prevent hospital-acquired sacrum pressure ulcers: An economic evaluation based on a publicly funded pragmatic randomized controlled trial linked with real-world data. J Tissue Viability. 2024 Aug 27:S0965-206X(24)00135-9.

Wieseler B, Neyt M, Kaiser T, Hulstaert F, Windeler J. Replacing RCTs with real world data for regulatory decision making: a self-fulfilling prophecy? BMJ. 2023 Mar 2;380:e073100. 

Neyt M, Devos C, Thiry N, Silversmit G, De Gendt C, Van Damme N, Castanares-Zapatero D, Hulstaert F, Verleye L. Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications. Eur J Cancer. 2023 Mar;182:23-37. 

Neyt M, Gerkens S, San Miguel L, Vinck I, Thiry N, Cleemput I. An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied. Health Policy. 2020 Sep;124(9):959-964.

Neyt M, Vlayen J, Devriese S, Camberlin C. First- and second-line bevacizumab in ovarian cancer: a Belgian cost-utility analysis. PLoS One. 2018 Apr 9;13(4).

Neyt M. Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water. Pharmacoeconomics. 2018 Jan;36(1):1-3.

Neyt M, Christiaens T, Demotes J, Walley T, Hulstaert F. Publicly funded practice-oriented clinical trials: of importance for healthcare payers. J Comp Eff Res. 2016 Nov;5(6):551-560.

Cleemput I, Neyt M. Which quality of life measures fit your relative effectiveness assessment? Int J Technol Assess Health Care. 2015 Jan;31(3):147-53.

Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014 Nov 7;4(11)

Neyt M, Chalon PX. Search MEDLINE for Economic Evaluations: Tips to Translate an OVID Strategy into a PubMed One. Pharmacoeconomics. 2013 Dec;31(12):1087-90.

Neyt M, Van den Bruel A. The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator. Eur J Health Econ. 2012 Aug;13(4):379-80.

Van Brabandt H, Neyt M, Hulstaert F. Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ. 2012 Jul 31;345:e4710.

Neyt M, Cleemput I, Thiry N, De Laet C. Calculating an intervention's (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data. Health Policy. 2012 Jul;106(2):207-10.

Neyt M, Van Brabandt H. Cost-effectiveness of transcatheter aortic valve replacement: overoptimistic study results and a call for publication of complete trial results. Heart. 2012 Jul;98(13):1031-3.

Neyt M, Van Brabandt H, Devriese S, Van De Sande S. A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open. 2012 May 4;2(3).

Selection of reports (related to ME-TA projects)

Neyt M, Christiaens A, Aloi M, de Ridder L, Croft NM, Koletzko S, Levine A, Turner D, Russell RK, Ruemmele FM, Veereman G. Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment. JMIR Form Res. 2021 Jan 25;5(1).

Review economic literature determining Lynch syndrome in patients with colorectal carcinoma: Neyt M. [Is het bij patiënten met colorectaal carcinoom (<50 jaar,50-70 jaar en >70 jaar) kosteneffectief om een MSI/IHC onderzoek uit tevoeren (om Lynch syndroom te bepalen)?] (in Dutch) 2014. Report for Integraal Kankercentrum Nederland (IKNL, the Netherlands). 

Health Technology Assessment of coronary heart disease diagnostics: Van den Bruel A, Neyt M, Smit Y, Vlayen J. [Diagnostiek coronaire ziekten] (in Dutch) 2013. Report for College voor Zorgverzekeringen (CVZ, the Netherlands)

Health Technology Assessment of the use of left ventricular assist devices as destination therapy for end-stage heart failure: Neyt M, Smit Y, Van den Bruel A, Vlayen J. [Left Ventricular Assist Device (LVAD) toegepast als bestemmingstherapie bij patiënten met eindstadium hartfalen] (in Dutch) 2011. Report for College voor Zorgverzekeringen (CVZ, the Netherlands).

• Neyt M, Van den Bruel A, Smit Y, De Jonge N, Vlayen J. The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations. Ann Cardiothorac Surg. 2014;3(5):451-461.

• Neyt M, Van den Bruel A, Smit Y, De Jonge N, Erasmus M, Van Dijk D, Vlayen J. Cost-effectiveness of continuous-flow left ventricular assist devices. Int J Technol Assess Health Care. 2013 Jul;29(3):254-60.

Literature review on the following aspects in the systemic treatment of metastatic renal cell carcinoma: safety, professional aspects, societal aspects (epidemiology) and cost effectiveness. (in Dutch) 2010. (IKNL, the Netherlands)